世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バイオシミュレーション市場の規模、シェア、動向分析レポート:製品別(ソフトウェア、サービス)、用途別(医薬品開発、創薬)、エンドユーザー別、地域別、セグメント別予測、2022年〜2030年


Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2022 - 2030

バイオシミュレーション市場の成長と動向 グランドビューリサーチ社の最新レポートによると、世界のバイオシミュレーション市場規模は2030年までに99億5000万米ドルに達すると予想されています。同市場は... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2022年6月28日 US$5,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
145 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

バイオシミュレーション市場の成長と動向

グランドビューリサーチ社の最新レポートによると、世界のバイオシミュレーション市場規模は2030年までに99億5000万米ドルに達すると予想されています。同市場は2022年から2030年にかけてCAGR16.9%で拡大すると予測されています。市場成長の主な要因としては、慢性疾患の発生率の増加、医療のデジタル化の進展、臨床試験や研究におけるバイオシミュレーションソリューションの利用が挙げられます。

急性疾患や慢性疾患が蔓延する中で創薬開発の必要性が高まり、研究開発活動への資金配分が増加し、バイオシミュレーションソリューションの採用が推進されています。また、薬剤の減少率の高さは臨床試験のコスト増につながるため、インシリコバイオロジー・アプローチを取り入れることが臨床上の緊急課題となっていると考えられます。このアプローチでは、生物学的相互作用を予測することで薬剤の失敗確率を大幅に低減し、全体的なコストを削減します。

薬剤の再発率や薬剤耐性例の増加、AIDSなどの疾患を治療するための薬剤が限られていることから、薬剤開発や創薬などの用途でバイオシミュレーションを導入することが臨床的に強く求められています。

また、COVID-19 の大流行も市場の成長に大きな影響を与えた。例えばSimulations Plusは、2020年3月にCOVID-19研究に携わるあらゆる組織へのコンサルティング支援を迅速化するStrategiesPlus COVID-19 ACT Programを開始した。同社は、2020年11月時点では、同社の事業に重大な悪影響はないと宣言している。しかし、COVID-19の継続的な拡大や、感染国政府の対策により、サプライチェーンが混乱し、同社の事業および財務業績に悪影響が及ぶ可能性がある。

バイオシミュレーションソフトウェアおよびサービスに対する需要の高まりは、その高い費用対効果にも起因しています。バイオシミュレーションソリューションは、製品開発の初期段階における治験薬の毒性、副作用、有効性をコスト効率よく予測できるため、後期段階での薬剤再発や有害事象の発生確率を抑えることができます。

市場プレイヤーは、市場での競争力を維持するために、買収、合併、パートナーシップ、製品の発売など、多くの戦略的イニシアティブに投資しています。例えば、2022年1月、Simulations Plus Inc.は、現在の動物の生理学的薬物動態(PBPK)モデルの検証のために、動物医療企業と協力しました。この資金提供によるコラボレーションで、同社はGastroPlusプラットフォームに重要な新しい種を追加することを目指した。さらに、2021年11月、横河電機は、バイオプロセスのソフトウェアとサービスを開発・提供するドイツのInsilico Biotechnology AGを買収した。

バイオシミュレーション市場レポートハイライト

- 製品別では、2021年にソフトウェアが市場を支配した。これは、研究要件に合った幅広い用途別ソフトウェアが入手可能であることに起因しています。さらに、バイオシミュレーションソフトウェアは臨床試験で使用されており、モデリングや標的薬剤の特定も容易になります

- 2021年、医薬品開発アプリケーション分野が55.0%以上の最大の売上シェアを占めた

- エンドユーザー別では、戦略的イニシアチブの増加により、製薬会社およびバイオテクノロジー会社が2021年に最大の収益シェアを占めた

- 北米は2021年に45.0%超の最大売上高シェアを獲得。有利な診療報酬の枠組み(特に医療費適正化法の施行後)と高度な医療インフラの存在が、予測期間中に同地域の市場を牽引すると予想される

- アジア太平洋地域は、CRO数の増加、医療ITへの支出の増加、医療インフラの急速な進化により、予測期間中に大きく成長することが予想される



ページTOPに戻る


目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 segment scope
1.1.2 regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
Chapter 2 Executive Summary
2.1 Biosimulation Market Summary
Chapter 3 Biosimulation Market Variables, Trends & Scope
3.1 Biosimulation Market Segmentation and Scope
3.2 Biosimulation Market Dynamics
3.2.1 Market driver analysis
3.2.2 Impact analysis
3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs
3.2.2.2 Growing number of relapse cases due to increasing drug resistance
3.2.2.3 Rising Technological advancements
3.2.2.4 Increasing need to reduce drug discovery and development costs
3.2.2.5 accelerating formulation development and saving costly studies
3.2.2.6 Increasing investments in the life sciences industry
3.2.2.7 Increasing use of personalized medicine
3.2.3 Market restraint analysis
3.2.4 Impact analysis
3.2.4.1 Lack of standardization
3.2.4.2 Shortage of skilled professionals
3.2.4.3 Intellectual property protection and public policy issues
3.3 Penetration and Growth Prospect Mapping, 2021
3.4 Pricing Analysis
3.5 Biosimulation Market Analysis Tools: Porters
3.5.1 bargaining power of Suppliers: Low
3.5.2 bargaining power of Buyers: Moderate
3.5.3 Therat of Substitutes: Low
3.5.4 Threat of New Entrants: High
3.5.5 Competitive Rivalry: High
3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
3.6.1 Political/Legal Landscape
3.6.2 Economic Landscape
3.6.3 Technology Landscape
Chapter 4 Biosimulation Market: Impact of COVID-19
4.1 Impact of Covid-19 on the Biosimulation Market
4.1.1 Current And Future Impact Analysis
4.1.2 Impact of covid-19 on market players
4.1.3 Disease Prevalence Analysis
Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million)
5.1 Definition and Scope
5.2 Product Market Share Analysis, 2021 & 2030
5.3 Biosimulation Market, by Product, 2017 - 2030
5.4 Software
5.4.1 software market, 2017 - 2030 (USD Million)
5.5 Services
5.5.1 Services market, 2017 - 2030 (USD Million)
5.5.2 In-house Services
5.5.2.1 In-house Services market, 2017 - 2030 (USD Million)
5.5.3 Contract Services
5.5.3.1 Contract Services market, 2017 - 2030 (USD Million)
Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2021 & 2030
6.3 Biosimulation Market, by Application, 2017 - 2030
6.4 Drug Development
6.4.1 drug development market, 2017 - 2030 (USD Million)
6.5 Drug Discovery
6.5.1 Drug Discovery market, 2017 - 2030 (USD Million)
6.6 Others
6.6.1 Others market, 2017 - 2030 (USD Million)
Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2021 & 2030
7.3 Global Biosimulation Market, by End-use, 2017 - 2030
7.4 Pharmaceutical & Biotechnology Companies
7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
7.5 CROs
7.5.1 CROs market, 2017 - 2030 (USD million)
7.6 Regulatory Authorities
7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million)
7.7 Academic Research Institutions
7.7.1 Academic research institutions market, 2017 - 2030 (USD million)
Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2021 & 2030
8.3 Regional Market Snapshot
8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030
8.5 North America
8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021
8.5.2 U.S.
8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million)
8.5.3 Canada
8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million)
8.6 Europe
8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021
8.6.2 U.K.
8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million)
8.6.3 Germany
8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million)
8.6.4 France
8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million)
8.7 Asia Pacific
8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021
8.7.2 Japan
8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million)
8.7.3 China
8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million)
8.7.4 India
8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million)
8.8 Latin America
8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021
8.8.2 Brazil
8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million)
8.8.3 Mexico
8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million)
8.9 MEA
8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021
8.9.2 South Africa
8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million)
Chapter 9 Biosimulation Market - Competitive Analysis
9.1 Strategy Framework
9.2 Market Participant Categorization
9.3 Public Companies
9.3.1 Company market position analysis
9.3.2 Comparative analysis by product category
9.4 Private Companies
9.4.1 List of Private companies
9.4.2 List of Emerging companies in the Asia Pacific Region
Chapter 10 Biosimulation Market - Company Profiles
10.1 Certara, USA
10.1.1 Company overview
10.1.2 Financial performance
10.1.3 Product benchmarking
10.1.4 Strategic initiatives
10.2 Simulations Plus
10.2.1 Company overview
10.2.2 Financial performance
10.2.3 Product benchmarking
10.2.4 Strategic initiatives
10.3 Dassault Systèmes
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Schrödinger, Inc.
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 Advanced Chemistry Development
10.5.1 Company overview
10.5.2 Product benchmarking
10.5.3 Strategic initiatives
10.6 Chemical Computing Group ULC
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 Physiomics Plc
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Product benchmarking
10.7.4 Strategic initiatives
10.8 Rosa & Co. LLC
10.8.1 Company overview
10.8.2 Product benchmarking
10.8.3 Strategic initiatives
10.9 Biosimulation Consulting Inc.
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Service benchmarking
10.10 Genedata AG
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Instem Group of Companies
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 PPD, Inc.
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Service benchmarking
10.12.4 Strategic initiatives
10.13 Yokogawa Insilico Biotechnology GmbH
10.13.1 Company overview
10.13.2 Product benchmarking
10.13.3 Strategic initiatives
10.14 Immunetrics
10.14.1 Company overview
10.14.2 Product benchmarking
Chapter 11 KOL Commentary

 

ページTOPに戻る


 

Summary

Biosimulation Market Growth & Trends

The global biosimulation market size is expected to reach USD 9.95 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.9% from 2022 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights

• By product, software dominated the market in 2021. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and targets drug identification

• The drug development application segment accounted for the largest revenue share of more than 55.0% in 2021

• By end-use, pharmaceutical and biotechnology companies held the largest revenue share in 2021 due to the increasing strategic initiatives

• North America grabbed the largest revenue share of over 45.0% in 2021. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to drive the regional market over the forecast period

• The Asia Pacific region is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 segment scope
1.1.2 regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
Chapter 2 Executive Summary
2.1 Biosimulation Market Summary
Chapter 3 Biosimulation Market Variables, Trends & Scope
3.1 Biosimulation Market Segmentation and Scope
3.2 Biosimulation Market Dynamics
3.2.1 Market driver analysis
3.2.2 Impact analysis
3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs
3.2.2.2 Growing number of relapse cases due to increasing drug resistance
3.2.2.3 Rising Technological advancements
3.2.2.4 Increasing need to reduce drug discovery and development costs
3.2.2.5 accelerating formulation development and saving costly studies
3.2.2.6 Increasing investments in the life sciences industry
3.2.2.7 Increasing use of personalized medicine
3.2.3 Market restraint analysis
3.2.4 Impact analysis
3.2.4.1 Lack of standardization
3.2.4.2 Shortage of skilled professionals
3.2.4.3 Intellectual property protection and public policy issues
3.3 Penetration and Growth Prospect Mapping, 2021
3.4 Pricing Analysis
3.5 Biosimulation Market Analysis Tools: Porters
3.5.1 bargaining power of Suppliers: Low
3.5.2 bargaining power of Buyers: Moderate
3.5.3 Therat of Substitutes: Low
3.5.4 Threat of New Entrants: High
3.5.5 Competitive Rivalry: High
3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
3.6.1 Political/Legal Landscape
3.6.2 Economic Landscape
3.6.3 Technology Landscape
Chapter 4 Biosimulation Market: Impact of COVID-19
4.1 Impact of Covid-19 on the Biosimulation Market
4.1.1 Current And Future Impact Analysis
4.1.2 Impact of covid-19 on market players
4.1.3 Disease Prevalence Analysis
Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million)
5.1 Definition and Scope
5.2 Product Market Share Analysis, 2021 & 2030
5.3 Biosimulation Market, by Product, 2017 - 2030
5.4 Software
5.4.1 software market, 2017 - 2030 (USD Million)
5.5 Services
5.5.1 Services market, 2017 - 2030 (USD Million)
5.5.2 In-house Services
5.5.2.1 In-house Services market, 2017 - 2030 (USD Million)
5.5.3 Contract Services
5.5.3.1 Contract Services market, 2017 - 2030 (USD Million)
Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2021 & 2030
6.3 Biosimulation Market, by Application, 2017 - 2030
6.4 Drug Development
6.4.1 drug development market, 2017 - 2030 (USD Million)
6.5 Drug Discovery
6.5.1 Drug Discovery market, 2017 - 2030 (USD Million)
6.6 Others
6.6.1 Others market, 2017 - 2030 (USD Million)
Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2021 & 2030
7.3 Global Biosimulation Market, by End-use, 2017 - 2030
7.4 Pharmaceutical & Biotechnology Companies
7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
7.5 CROs
7.5.1 CROs market, 2017 - 2030 (USD million)
7.6 Regulatory Authorities
7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million)
7.7 Academic Research Institutions
7.7.1 Academic research institutions market, 2017 - 2030 (USD million)
Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2021 & 2030
8.3 Regional Market Snapshot
8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030
8.5 North America
8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021
8.5.2 U.S.
8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million)
8.5.3 Canada
8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million)
8.6 Europe
8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021
8.6.2 U.K.
8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million)
8.6.3 Germany
8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million)
8.6.4 France
8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million)
8.7 Asia Pacific
8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021
8.7.2 Japan
8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million)
8.7.3 China
8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million)
8.7.4 India
8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million)
8.8 Latin America
8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021
8.8.2 Brazil
8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million)
8.8.3 Mexico
8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million)
8.9 MEA
8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021
8.9.2 South Africa
8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million)
Chapter 9 Biosimulation Market - Competitive Analysis
9.1 Strategy Framework
9.2 Market Participant Categorization
9.3 Public Companies
9.3.1 Company market position analysis
9.3.2 Comparative analysis by product category
9.4 Private Companies
9.4.1 List of Private companies
9.4.2 List of Emerging companies in the Asia Pacific Region
Chapter 10 Biosimulation Market - Company Profiles
10.1 Certara, USA
10.1.1 Company overview
10.1.2 Financial performance
10.1.3 Product benchmarking
10.1.4 Strategic initiatives
10.2 Simulations Plus
10.2.1 Company overview
10.2.2 Financial performance
10.2.3 Product benchmarking
10.2.4 Strategic initiatives
10.3 Dassault Systèmes
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Schrödinger, Inc.
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 Advanced Chemistry Development
10.5.1 Company overview
10.5.2 Product benchmarking
10.5.3 Strategic initiatives
10.6 Chemical Computing Group ULC
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 Physiomics Plc
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Product benchmarking
10.7.4 Strategic initiatives
10.8 Rosa & Co. LLC
10.8.1 Company overview
10.8.2 Product benchmarking
10.8.3 Strategic initiatives
10.9 Biosimulation Consulting Inc.
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Service benchmarking
10.10 Genedata AG
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Instem Group of Companies
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 PPD, Inc.
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Service benchmarking
10.12.4 Strategic initiatives
10.13 Yokogawa Insilico Biotechnology GmbH
10.13.1 Company overview
10.13.2 Product benchmarking
10.13.3 Strategic initiatives
10.14 Immunetrics
10.14.1 Company overview
10.14.2 Product benchmarking
Chapter 11 KOL Commentary

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(薬学的薬物)の最新刊レポート

Grand View Research社のその他分野での最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る